Kynurenine, the first metabolite product in the IDO-dependent tryptophan degradation pathway, can be exported to the tumor microenvironment by cancer cells to inhibit antitumor immunity and prevent tumor clearance37,46,47. This evidence concerns the gene IDO1 and cancer.